Dusseldorf - Delayed Quote EUR

Shanghai Fosun Pharmaceutical (Group) Co Ltd (08HH.DU)

1.5630

-0.0300

(-1.88%)

As of 4:30:23 PM GMT+2. Market Open.

Fosun Pharma Announces 2024 Annual Results

On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December 2024 ("the Reporting Period").

PR Newswire last month

SFOSF
Fosun Pharma to sell United Family Healthcare

The decision entails the transfer of 9.4 million shares at $13.2 each.

Hospital Management last month

SFOSF
Ardelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell

Ardelyx (ARDX) said Wednesday that a new drug application for tenapanor for the treatment of hyperph

PREMIUM
MT Newswires 2 months ago

ARDX

SFOSF
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun Pharma Industrial"), has received approval from the National Medical Products Administration ("NMPA") for the New Drug Application ("NDA") for Tenapanor Hydrochloride Tablets (Chinese trade name: Wan Ti Le, the "New Drug"), an innovative phosphate absorption inhibitor with a novel mechanism, w

PR Newswire 2 months ago

SFOSF
Fosun Pharmaceutical Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as drug research and development, medical imaging, and precision medicine through both independe

PR Newswire 2 months ago

SFOSF
Fosun Pharma Announces 2024Q3 Financial Results

On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its operating performance for the first three quarters of 2024. From January to September 2024, Fosun Pharma achieved revenue of RMB30.91 billion, an increase of about 5.74% YoY after excluding COVID-related products. The net profit attributable to owners of the parent of the Group after deducting extraordinary gain or loss amounted to RMB1.84 billion, up by

PR Newswire 6 months ago

SFOSF
Fosun Pharma Announces 2024 Interim Results

On August 27, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH; 02196.HK), announced its operating performance for the first half of 2024 (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue of RMB20.46 billion, an increase of 5.31% YoY after excluding COVID-related products. The net profit attributable to owners of the parent of the Group after deducting extraordinary gain or loss amounted to RMB1.3 billion. In

PR Newswire 8 months ago

SFOSF

Performance Overview

Return	08HH.DU	SSE Composite Index (000001.SS)
YTD	-7.24%	+0.69%
1-Year	+8.17%	+7.21%
3-Year	+8.17%	+9.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Shanghai Fosun Pharmaceutical (Group) Co Ltd (08HH.DU)

Fosun Pharma Announces 2024 Annual Results

Fosun Pharma to sell United Family Healthcare

Ardelyx Says China Approves New Drug Application for Hyperphosphatemia Treatment Tenapanor; Shares Up Pre-Bell

Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)

Fosun Pharmaceutical Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation

Fosun Pharma Announces 2024Q3 Financial Results

Fosun Pharma Announces 2024 Interim Results

Performance Overview